U.S. equities finished mixed on Monday amid quiet trading as focus remained on the aftermath of Hurricane Harvey and the heavy flooding in Houston. But there was action if you knew where to look, with precious metals in particular on the move.
A few dynamics are driving this. For one, headlines are being filled more and more with dread about the approaching debt ceiling debacle. Two, the Federal Reserve is preparing for the start of “quantitative tightening” next month. And three, stocks look vulnerable to a pullback here as breadth continues to narrow, risk measures remain red-hot, and valuations are at extremes.
In the end, the Dow Jones Industrial Average lost a fraction, the S&P 500 gained 0.1%, the Nasdaq Composite gained 0.3% and the Russell 2000 added 0.4%, marginally retaking its 200-day moving average.
Elsewhere, Treasury bonds were mixed, the dollar was under pressure, gold gained 1.3% and oil fell 2.7% as Harvey caused refineries to shut down and would worsen the crude oil oversupply.
Best Gold Stocks To Buy Right Now: Gentex Corporation(GNTX)
Advisors’ Opinion:
- [By Lisa Levin] Related TRST Earnings Scheduled For October 21, 2016 Major Accounting Changes Are Coming To The Financial Industry
Related MORN One Of The World's Most Powerful Women, Fidelity Personal Investing President Kathleen Murphy, To Tell Her Story At The Benzinga Global Fintech Awards The 2017 Benzinga Global Fintech Awards Will Include An 'Unprecedented Group' Of Judges Morningstar Packs Conference Lineup For Financial Advisors (Investor’s Business Daily) Companies Reporting Before The Bell
Rockwell Collins, Inc. (NYSE: COL) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.33 billion.
General Electric Company (NYSE: GE) is expected to report quarterly earnings at $0.17 per share on revenue of $26.46 billion.
Honeywell International Inc. (NYSE: HON) is estimated to report quarterly earnings at $1.60 per share on revenue of $9.32 billion.
Interpublic Group of Companies Inc (NYSE: IPG) is expected to report quarterly earnings at $0.03 per share on revenue of $1.76 billion.
Schlumberger Limited. (NYSE: SLB) is estimated to report quarterly earnings at $0.26 per share on revenue of $7.02 billion.
SunTrust Banks, Inc. (NYSE: STI) is expected to report quarterly earnings at $0.83 per share on revenue of $2.21 billion.
ManpowerGroup Inc. (NYSE: MAN) is projected to report quarterly earnings at $1.11 per share on revenue of $4.68 billion.
Kansas City Southern (NYSE: KSU) is estimated to report quarterly earnings at $1.15 per share on revenue of $593.82 million.
Stanley Black & Decker, Inc. (NYSE: SWK) is projected to report quarterly earnings at $1.19 per share on revenue of $2.74 billion.
WABCO Holdings Inc. (NYSE: WBC) is estimated to report quarterly earnings at $1.44 per share on revenue of $721.89 million.
Best Gold Stocks To Buy Right Now: Arena Pharmaceuticals, Inc.(ARNA)
Advisors’ Opinion:
- [By Paul Ausick]
Arena Pharmaceuticals Inc. (NASDAQ: ARNA) posted a new 52-week low of $1.20 on Tuesday, down about 19% compared with Monday’s closing price of $1.48. The stock’s 52-week high is $2.16. Volume was about 10% below the daily average of around 3.8 million shares. The company priced a secondary offering of 60 million shares at $1.15 per share, a path guaranteed to enrage existing investors.
- [By Lisa Levin]
Shares of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) were down around 18 percent to $1.22. Arena Pharmaceuticals priced its 60 million share offering at $1.15 per share.
- [By Lisa Levin]
In trading on Friday, healthcare shares fell by 0.09 percent. Meanwhile, top losers in the sector included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), down 6 percent, and Omeros Corporation (NASDAQ: OMER), down 5 percent.
- [By Peter Graham]
The Q4 2016 earnings report for small cap obesity drug stock Arena Pharmaceuticals, Inc (NASDAQ: ARNA) is scheduled for after the market closes onTuesday (March 14th). Last June,Arena Pharmaceuticals announced a strategic shifting of priorities to emphasize its proprietary clinical stage pipeline and the implementation of additional cost reductions to streamline the organization to support its development programs. Among the actions to be taken is the layoff of 73% of the companys workforce which will cost approximately $6.1 million.
- [By Keith Speights]
Eisai partnered with Arena Pharmaceuticals (NASDAQ:ARNA) several years ago on obesity drug Belviq. The drug won U.S. regulatory approval in 2012, but sales have been underwhelming. As a result, Arena sold Belviq to Eisai earlier this year.
Best Gold Stocks To Buy Right Now: Beazer Homes USA, Inc.(BZH)
Advisors’ Opinion:
- [By Dan Caplinger]
The stock market performed well on Tuesday, responding to steady improvement among many companies as earnings season kicked into high gear. Although political issues are likely to remain in the spotlight for some investors for the foreseeable future, many market participants are looking to economic and business issues in driving their investing decisions. Major market benchmarks finished the day with gains of 0.5% to 1%, but some stocks did much better. Among the best performers on the day were Allegheny Technologies (NYSE:ATI), II-VI (NASDAQ:IIVI), and Beazer Homes (NYSE:BZH). Below, we’ll look more closely at these stocks to tell you why they did so well.
Best Gold Stocks To Buy Right Now: Abbott Laboratories(ABT)
Advisors’ Opinion:
- [By Matt Hogan]
AbbVie has distributed a significant amount of its earnings in the form of dividends (~60 percent) since the company spun off from Abbott Laboratories (NYSE: ABT) in 2013. The company appears to be trading at a 10 percent discount to fair value when applying similar assumptions in the 5-year dividend discount model as shown below.
- [By Sean Williams]
Finally, and as the icing on the cake, Wall Street uncovered via a Securities and Exchange Commission filing that Abbott Laboratories (NYSE:ABT) sold 44 million shares of Mylan stock at $41.60, reducing its remaining position in the company to 25.75 million shares, or about 4.8% of its outstanding shares. Considering all the issues Mylan has had recently, the fact that Abbott substantially pared its large holding in the company is a bit worrisome.
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Abbott Laboratories (ABT) , Dycom Industries (DY) and Howard Hughes (HHC) .
Cramer was bearish on Headwaters (HW) , EnergySolutions (ES) , Western Refining (WNR) and Horizon Pharmaceuticals (HZNP) .
Best Gold Stocks To Buy Right Now: Pinnacle Entertainment Inc.(PNK)
Advisors’ Opinion:
- [By Ben Levisohn]
Pinnacle Entertainment (PNK) has gained 56% this year; Las Vegas Sands (LVS) has climbed 38%. And Deutsche Bank has nice things to say about both today.
Bloomberg
First Pinnacle. Deutsche Bank’s Carlo Santarelli ponders the stock’s big move and comes away still seeing value in its shares. He writes:
When we upgraded PNK in April, our thesis centered on the FCF strength of the combined entities [Pinnacle completed its acquisition of Ameristar Casinos on Aug. 14], a handful of favorable catalysts, easing regional gaming comps, & an inexpensive relative valuation. Given the shares’ sizeable move since then, we believe it is worth revisiting the investment case. Post the announcement of several asset sales and the closing of the transaction, we are adjusting our estimates, raising our PT to $30 from $24, and maintaining our bullish view at current levels given what we still believe to be an attractive free cash flow valuation, meaningful potential synergy realization beyond the $40 mm of announced benefits, and a free option on a lagging regional recovery.
Santarelli also revisited Las Vegas Sands and there too, he likes what he sees. He writes:
With…LVS at [a share price level] that have been challenging to break from over the last year plus, we believe this time is different and hence we see continued upward momentum…In the case of LVS, we see; 1) meaningful mass market strength continuing through year end, setting the stage for upward company and market estimate revisions for 2014, 2) continued cash flow appreciation and capital returns serving as downside protection and positive catalysts, and 3) continued shared gains, largely driven by table optimization and mass market strength, driving both estimates and sentiment.
He also likes Wynn Resorts (WYNN), despite its 34% gain.Santarelli writes:
As for WYNN, we believe near-term estimates continue to take a back seat to capital return
